Sikes-Keilp, Christopher http://orcid.org/0000-0002-4337-1229
Rubinow, David R. http://orcid.org/0000-0003-0815-2263
Article History
Accepted: 20 July 2023
First Online: 5 August 2023
Declarations
:
: No funding was received for the preparation of this manuscript.
: Dr. Rubinow is on the Scientific Advisory Board of (and has received honoraria and stock options from) Sage Therapeutics. He is also on the Scientific Advisory Boards of Sensorium Therapeutics and Embarq Neuro. He also has consulted to Arrivo Therapeutics. Dr. Sikes-Keilp reports no conflicts of interest.
: No ethics approval for this review was required.
: Not applicable.
: Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
: No software application or custom code was used in the generation of this manuscript.
: CSK and DRR both made substantial contributions to the written manuscript, including conceptualization, drafting, and critical review for important intellectual content. Both authors provided final approval of the version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
: Not applicable.